Cyclophosphamide + FLUDARABINE + Prulacabtagene Leucel for scleroderma, systemic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Apr 2024: Trial registered, NCT06375993
  2. 10 Nov 2024: Trial started, NCT06375993

The trials

NCT06375993: A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

State
Under way
Phase
Phase 1
People
180 planned
Started
10 Nov 2024
Primary completion
Dec 2026
Arms
ADI-001 Dose Escalation, ADI-001 Dose Extension, ADI-001 Dose Expansion
Results
None posted
  1. 19 Apr 2024: Trial registered
  2. 10 Nov 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.